Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Net Cash Flow (2023 - 2025)

Immunome's Net Cash Flow history spans 3 years, with the latest figure at $380.8 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 3217.32% year-over-year to $380.8 million; the TTM value through Dec 2025 reached $510.2 million, up 1042.19%, while the annual FY2025 figure was $510.2 million, 1042.19% up from the prior year.
  • Net Cash Flow reached $380.8 million in Q4 2025 per IMNM's latest filing, up from $128.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $380.8 million in Q4 2025 to a low of -$113.6 million in Q2 2025.
  • Average Net Cash Flow over 3 years is $52.8 million, with a median of $16.1 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: tumbled 1637.53% in 2024, then skyrocketed 3217.32% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at $8.0 million in 2023, then tumbled by 251.99% to -$12.2 million in 2024, then surged by 3217.32% to $380.8 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Net Cash Flow are $380.8 million (Q4 2025), $128.8 million (Q3 2025), and -$113.6 million (Q2 2025).